Pharmaceuticals and healthcare

Vischer advises Lundbeck on acquisition of Prexton Therapeutics

Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) announced the signing of a definitive agreement in which Lundbeck will acquire Prexton. Under terms of the agreement, Lundbeck will pay €100m upfront and is furthermore required to later pay up to €805m in development and sales milestones to the group of current owners. VISCHER advised Lundbeck […]

No 5 Chambers seminar: What a mesh!

What a mesh! | Birmingham | 19 March 2018 Mamta Gupta and guest speaker Dr Wael Agur (who recently appeared on BBC’s Panorama) will give a talk on vaginal mesh going into the reasons as to its use along with the risks and benefits, the relevant guidance in the UK and the controversy with using this product. The seminar […]

Walder Wyss advises Auris Medical on reverse split

On March 12, 2018, the extraordinary general meeting of shareholders approved the merger of Auris Medical Holding AG, a Swiss company listed on Nasdaq, into Auris Medical NewCo Holding AG, a newly incorporated, wholly-owned Swiss Subsidiary. The Merger became effective on March 13, 2018, upon its registration in the Commercial Register in the Canton of […]

Khaitan & Co advises Torrent Pharmaceuticals on acquisition of Unichem businesses

Khaitan & Co advised Torrent Pharmaceuticals Limited in relation to acquisition financing facility of INR 2800 crores raised through a combination of loan and non-convertible debentures for the purpose of financing the acquisition of branded businesses of Unichem Laboratories Limited. Kumar Saurabh Singh (Partner), Soumava Chatterjee (Principal Associate) and Oindrila Bhowmik (Associate). Torrent Pharmaceuticals Limited, the flagship […]

Vischer advises Medartis on planned IPO on SIX Swiss Exchange

Medartis Holding AG, a leading original equipment manufacturer (OEM) specialized in medical devices for internal surgical bone fixation, announces its intention to conduct an initial public offering (IPO) on the SIX Swiss Exchange in the first half of 2018 to finance further growth. Founded in 1997 by Dr. h.c. Thomas Straumann, Medartis has emerged as […]

Vischer advises Polyphor on licensing agreement with Santhera

Polyphor AG, a clinical stage, privately held Swiss specialty pharma company, has entered into an exclusive, global license agreement with Santhera Pharmaceuticals to further develop and commercialize the inhaled neutrophil elastase inhibitor, POL6014, in Cystic Fibrosis (CF) and other neutrophilic lung diseases. Under the terms of the agreement, Polyphor will receive an upfront payment of […]

Daniel Brook, pharma litigation, Hogan Lovells

Brook, Daniel – Hogan Lovells

As a former chemistry student, Hogan Lovells IP partner Daniel Brook has honed his legal and science knowledge to become indispensable to several of the world’s largest pharmaceutical companies looking to safeguard their products. One of the most important judgments last year was Eli Lilly’s landmark patent trial against pharmaceutical rival Actavis. Brook took the […]

Kiran Bhogal Hill Dickinson

Bhogal, Kiran – Hill Dickinson

After arriving from Weightmans in January 2016, Kiran Bhogal was given the remit of creating a health practice of note within Hill Dickinson. Two years on from her arrival, she is doing just that. A steady 2016 became an excellent 2017 involving a landmark case taken to the Supreme Court, N v ACCG, and chairing […]

Louisa Ghevaert, Michelmores

Ghevaert, Louisa – Michelmores

Louisa Ghevaert’s practice is unusual in that it encompasses family law, fertility law and the medical sector. In 2008 she was part of the team that won the first case for overseas surrogacy, Re X and Y (Foreign Surrogacy), and a year later she co-founded the UK’s first specialist fertility firm. Now at Michelmores she […]

Register now to The Lawyer to access our latest news stories, read selected briefings from key firms and gain essential careers insight to help you make the most of your current and future roles.

Contact Us: if you have any questions regarding your subscription, call us on +44 (0)20 7292 3716 or email us at

Register now

Having problems?

Contact us on +44 (0)20 7292 3723 | email:

If you are looking for our Jobs site, please click here